Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease-Reference-Cited by-同舟云学术

Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease

Published:2007-02 Issue:2 Volume:39 Page:182-186
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Gilissen L.P.L.,Derijks L.J.J.,Verhoeven H.M.J.H.,Bierau J.,Hooymans P.M.,Hommes D.W.,Engels L.G.J.B.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis;Pearson;Ann Intern Med,1995

2. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, ciclosporine and methotrexate;Sandborn;Am J Gastroenterol,1996

3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement;Caprilli;Dig Liver Dis,2005

4. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy;Cuffari;Aliment Pharmacol Ther,2000

5. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations;Al Hadithy;Dig Liver Dis,2005

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency;Metabolites;2023-10-06

2. Implications of tioguanine dosing in IBD patients with a TPMT deficiency;2023-01-23

3. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease;Expert Opinion on Drug Metabolism & Toxicology;2021-12-02

4. Mean Corpuscular Volume to White Blood Cell Ratio for Thiopurine Monitoring in Pediatric Inflammatory Bowel Disease;Journal of Pediatric Gastroenterology & Nutrition;2019-07

5. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease;Clinical Pharmacokinetics;2018-03-06